Stockscreener 앱 받기
422.61
2.61%
-11.46
전일 마감가:
$434.07
열려 있는:
$429.9
하루 거래량:
798.22K
Relative Volume:
0.69
시가총액:
$55.39B
수익:
$3.21B
순이익/손실:
$43.57M
주가수익비율:
1,757.21
EPS:
0.2405
순현금흐름:
$221.36M
1주 성능:
-11.17%
1개월 성능:
-7.36%
6개월 성능:
+62.98%
1년 성능:
+56.60%
1일 변동 폭
$422.44
$431.50
1주일 범위
$422.44
$482.73
52주 변동 폭
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
422.55 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.80 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.02 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
836.27 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.19 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Top 20 biopharma companies Q3 2025 market cap up 4% despite headwinds - Yahoo Finance
Alnylam (NASDAQ: ALNY) to present Nov 10 & Nov 19 at UBS and Jefferies; live webcasts - Stock Titan
Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Business Wire
Royalty Pharma Acquires $310 Million Royalty Interest in Alnylam's AMVUTTRA from Blackstone Life Sciences - Quiver Quantitative
Hussman Strategic Advisors Inc. Sells 2,100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Why global investors buy Alnylam Pharmaceuticals Inc. (DUL) stock2025 Volatility Report & Weekly High Momentum Picks - newser.com
Is Alnylam Pharmaceuticals Inc. reversing from oversold territoryInflation Watch & Low Drawdown Investment Ideas - newser.com
Amalgamated Bank Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Assetmark Inc. Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Regression analysis insights on Alnylam Pharmaceuticals Inc. performancePortfolio Gains Report & Daily Risk Controlled Trade Plans - newser.com
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumWeekly Stock Report & Real-Time Sentiment Analysis - newser.com
Will Alnylam Pharmaceuticals Inc. continue its uptrendMarket Activity Summary & Fast Exit/Entry Strategy Plans - newser.com
Is Alnylam Pharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Review & Target Return Focused Picks - newser.com
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline - GlobeNewswire Inc.
How to monitor Alnylam Pharmaceuticals Inc. with trend dashboards2025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com
What data driven models say about Alnylam Pharmaceuticals Inc.’s futureTreasury Yields & Fast Exit and Entry Trade Guides - newser.com
What RSI levels show for Alnylam Pharmaceuticals Inc. (DUL) stock2025 Stock Rankings & Long-Term Investment Growth Plans - newser.com
Combining machine learning predictions for Alnylam Pharmaceuticals Inc.2025 Market Sentiment & Stepwise Entry and Exit Trade Signals - newser.com
Tredje AP fonden Has $3.98 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam (ALNY) Dropped from Goldman Sachs Conviction List - GuruFocus
How to recover losses in Alnylam Pharmaceuticals Inc. stock2025 Bull vs Bear & Comprehensive Market Scan Reports - newser.com
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flowsJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Has Alnylam Pharmaceuticals Inc. found a price floorJuly 2025 News Drivers & Weekly High Return Stock Forecasts - newser.com
Sumitomo Life Insurance Co. Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Published on: 2025-11-03 03:21:20 - newser.com
Is Alnylam Pharmaceuticals Inc. stock resilient to inflationJuly 2025 Sentiment & AI Driven Stock Price Forecasts - newser.com
How dovish Fed policy supports Alnylam Pharmaceuticals Inc. (DUL) stock2025 Historical Comparison & Real-Time Stock Entry Alerts - newser.com
Envestnet Asset Management Inc. Buys 23,749 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
How risky is Alnylam Pharmaceuticals Inc. (DUL) stock compared to peersEarnings Overview Report & Precise Buy Zone Tips - newser.com
Is it time to cut losses on Alnylam Pharmaceuticals Inc.July 2025 Earnings & Fast Entry and Exit Trade Plans - newser.com
Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.July 2025 Drop Watch & Stepwise Trade Execution Plans - newser.com
What downside risks could hit Alnylam Pharmaceuticals Inc. (DUL) stockOptions Play & Free Community Supported Trade Ideas - newser.com
Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesQuarterly Trade Summary & Community Consensus Trade Signals - newser.com
Alnylam Pharmaceuticals Hits Day Low of $436.51 Amid Price Pressure - Markets Mojo
Alnylam Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year - Yahoo Finance
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Benzinga
ANTIPODES PARTNERS Ltd Sells 36,750 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock vulnerable to rate hikes2025 Technical Overview & High Accuracy Trade Alerts - newser.com
Strs Ohio Has $9.83 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Focus Partners Advisor Solutions LLC Has $263,000 Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Why Alnylam Pharmaceuticals Inc. stock is recommended by analystsJuly 2025 Review & Capital Efficiency Focused Strategies - newser.com
What to do if you’re stuck in Alnylam Pharmaceuticals Inc.Wall Street Watch & Low Drawdown Investment Ideas - newser.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2025 Earnings Call Transcript - Insider Monkey
A Fresh Look at Alnylam Pharmaceuticals (ALNY) Valuation Following Q3 Profit Surge and Upgraded Guidance - simplywall.st
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alnylam Pharmaceuticals Inc 주식 (ALNY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Oct 02 '25 |
Sale |
452.05 |
8,924 |
4,034,085 |
65,409 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Oct 02 '25 |
Sale |
452.05 |
1,405 |
635,126 |
27,438 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Oct 02 '25 |
Sale |
452.05 |
2,441 |
1,103,451 |
25,231 |
| Garg Pushkal | EVP Chief R&D |
Oct 03 '25 |
Sale |
451.48 |
3,022 |
1,364,387 |
20,221 |
| Garg Pushkal | EVP Chief R&D |
Oct 02 '25 |
Sale |
452.05 |
2,937 |
1,327,675 |
23,243 |
1.30%
1.90%
자본화:
|
볼륨(24시간):